Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1
We are proud and overjoyed, the hard work of the ARTHEx’s team has earned recognition after our first-anniversary celebration. This month has been fascinating, bringing us several grants and awards at regional, national, and international levels. The €250K funding from the Neotec program has been a resounding success. Indeed, this is the most prestigious grant … Read more
Eric Marcusson joins ARTHEx’s Scientific Advisory Board
September 2020: ARTHEx expands its Scientific Advisory Board with the appointment of Eric G. Marcusson, who has an extensive experience of more than 20 years in preclinical drug development of RNA therapeutics. Currently, Dr. Marcusson has his own consultancy firm to provide expert advice to start-ups, pharma industry and venture capitalists. He is also co-founder … Read more
Dr Nicholas Jonhson, new Chief Medical Advisor
August 2020: After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1, associate professor of Neurology and Human and Molecular Genetics, vice chair of research … Read more
Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology
Funding will help advance development of company’s Myotonic Dystrophy therapy Valencia and Barcelona, Spain, and Paris, France, July 23, 2020 – Arthex Biotech (ARTHEx), a preclinical stage life sciences company focused on the development of the next generation antisense RNA therapies for the treatment of Myotonic Dystrophy Type 1 (DM1), today announces it has closed … Read more
International Myotonic Dystrophy Consortium
June 2019: The ARTHEx Biotech team at the International Myotonic Dystrophy Consortium held from 10 to 14 June 2019 in Gothenburg, Sweden. “Challenges in Myotonic Dystrophy – from basic science to therapy”.